Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms
Molecular Biology Reports · 2023
DOI: 10.1007/s11033-023-08511-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2023. Verfasst von Itır Şirinoğlu Demiriz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Internal Medicine, Hematology Unit, V.M. Medical Park Teaching Hospital, Istanbul Aydin University, Istanbul, Turk…. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Janus kinase 2 (JAK2) V617F gene mutation is an important marker for the diagnosis of Philadelphia negative Myeloproliferative neoplasms (MPN) which is subdivided into Polycythemia Vera (PV), Primary Myelofibrosis (PMF), and Essential Thrombocythemia (ET). The aim here is to investigate the JAK2 allele burden of the patients diagnosed with the subgroups of MPN and to demonstrate the alterations of hematological parameters and spleen size between diagnosis and 6 months of treatment. METHODS: A total of 107 patients with the diagnosis of MPN and negative Philadelphia chromosome, 51 males and 56 females with a mean age of 59,74 ± 16,41 years, were included in the study. Diagnosis of MPN was based on the World Health Organization (WHO) criteria. Subgroups of MPN distributed as 49,5% ET, 46,7% PV, and 3,8% PMF. Findings such as the age of the patients, JAK-2 allele burden, and laboratory findings of splenomegaly were examined at the time of diagnosis, 3rd month, and 6th month. JAK2 allele burden and spleen size were re-evaluated in 6th month. RESULTS: Our study confirmed the findings of high Hb, HCT, and RBC but low platelet values in PV patients with high JAK2 allele burden with respect to other groups, a positive correlation between JAK2 allele burden and LDH. CONCLUSIONS: A novel finding of our study is, that there is not any reducing effect of the phlebotomy on JAK2 allele burden in PV patients whether they receive phlebotomy or not. Evaluation of the spleen size alteration during 6 months within the subgroups demonstrated a decrease in PV and ET groups whereas no statistically significant difference was found in the PMF group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Internal Medicine, Hematology Unit, V.M. Medical Park Teaching Hospital, Istanbul Aydin University, Istanbul, Turkey. dritir@hotmail.com.
- Faculty of Medicine, Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Training & Research Hospital, University of Health Sciences, Istanbul, Turkey.
- Faculty of Medicine, Department of Medical Biochemistry, Istanbul Aydin University, Istanbul, Turkey.
- Faculty of Medicine, Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
- Faculty of Medicine, Department of Medical Biochemistry, Istanbul Aydin University, Istanbul, Turkey. zarghamin@gmail.com.
Zitieren
APA
Demiriz, I. Ş., Kazanci, M. H., Menfaatli, E., Jafari-Gharabaghlou, D., & Zarghami, N. (2023). Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms. Molecular Biology Reports. https://doi.org/10.1007/s11033-023-08511-4
Vancouver
Demiriz IŞ, Kazanci MH, Menfaatli E, Jafari-Gharabaghlou D, Zarghami N. Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms. Molecular Biology Reports. 2023. doi:10.1007/s11033-023-08511-4
BibTeX
@article{Demiriz2023,
author = {Demiriz, Itır Şirinoğlu and Kazanci, Mehmet Hanifi and Menfaatli, Esra and Jafari-Gharabaghlou, Davoud and Zarghami, Nosratollah},
title = {Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms},
journal = {Molecular Biology Reports},
year = {2023},
doi = {10.1007/s11033-023-08511-4}
}
EUVIMED